Evidence map›Paper›PMID 26960450›Full record

ArticleClinical rheumatology2016

The investigation of killer cell immunoglobulin-like receptor genotyping in patients with systemic lupus erytematosus and systemic sclerosis.

Jülide Duymaz Tozkır, Hilmi Tozkır, Hakan Gürkan, Salim Dönmez, Damla Eker, Gülsüm Emel Pamuk, Ömer Nuri Pamuk

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. The Role of Killer Ig-like Receptors in Diseases from A to Z.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Journal of immunology research · 2019
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jülide Duymaz TozkırHealth Services Vocational College, Trakya University, Edirne, Turkey. jduymaz@gmail.com.
Hilmi TozkırMedical Faculty, Division of Medical Genetics, Trakya University, Edirne, Turkey.
Hakan GürkanMedical Faculty, Division of Medical Genetics, Trakya University, Edirne, Turkey.
Salim DönmezMedical Faculty, Division of Rheumatology, Trakya University, Edirne, Turkey.
Damla EkerMedical Faculty, Division of Medical Genetics, Trakya University, Edirne, Turkey.
Gülsüm Emel PamukMedical Faculty, Division of Haematology, Trakya University, Edirne, Turkey.
Ömer Nuri PamukMedical Faculty, Division of Rheumatology, Trakya University, Edirne, Turkey.
Trakya University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by the production of autoantibodies and the involvement of multiple organ systems. Systemic sclerosis (SSc) is another autoimmune disease that causes fibrosis. We will aim to analyse the role of killer cell immunoglobulin-like receptor (KIR) genotypes and their existence with the respective HLA ligands in patients with SLE and SSc. Forty-five SLE, 25 SSc and 40 healthy controls were included. We examined the presence/absence of KIR2DL1, 2DL2, 2DL3, 2DL4, 2DL5A, 2DL5B, 2DS1, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 3DS1, 2DP1, 3DP1 and their known HLA ligands. In the SLE group, the KIR2DL5, KIR2DL5B and KIR2DS3 genes were significantly more frequent, and KIR2DL3 gene was significantly less than in controls (p values <0.05). In SSc patients, the KIR2DS3 gene was more frequent than in controls (p = 0.032). The KIR2DL3 gene was detected more frequently in controls while KIR2DS3 gene was more frequent in the patient group when SLE and SSc patients were combined (p values < 0.05). The KIR2DS2/HLA-C and KIR2DS2/HLA-C combinations were significantly more in both SLE and SSc groups than in controls. The KIR2DL2 and KIR2DL5B genes were protective from neurologic involvement in SLE patients (p values <0.05). The variations of some KIR genes such as KIR2DL5, KIR2DL5B, KIR2DS3 and KIR2DL3 may have a role in the pathogenesis of SLE and SSc. Also, the presence of KIR2DL2 and KIR2DL5B may cause major organ involvement, like neurologic involvement, in SLE.

Indexed as

GenotypeAdultAllelesCase-Control StudiesFemaleGene FrequencyHaplotypesHLA-C AntigensHumansLigandsLupus Erythematosus, SystemicMaleReceptors, KIRReceptors, KIR2DL2Receptors, KIR2DL3Receptors, KIR2DL5HLA-C AntigensKIR2DL2 protein, humanKIR2DL3 protein, humanKIR2DL5B protein, humanKIR2DS3 protein, humanLigandsReceptors, KIRReceptors, KIR2DL2Receptors, KIR2DL3Receptors, KIR2DL5GeneticKiller cell immunoglobulin-like receptors (KIRs)Systemic lupus erythematosus (SLE)Systemic sclerosis (SSc)

Identifiers

PMID26960450
OpenAlexW2302291481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.